Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHEoN: Zimberelimab and Etrumadenant with Chemoradiation in Head and Neck Cancer
NCT04892875Phase 1Withdrawn
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of zimberelimab and etrumadenant in head and neck squamous cell carcinoma (HNSCC) (3 cohorts). Primary endpoints: Incidence of adverse events, Incidence of dose limiting toxicities and 5 more. Planned start Dec 2023; status: withdrawn.
02
Drugs
zimberelimabetrumadenant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04892875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892875.